10 questions about 4-aminopyridine and the treatment of multiple sclerosis.
Bever
Christopher T
CT
Research and Neurology Services, VA Maryland Healthcare System, VA Multiple Sclerosis Center of Excellence-East, Baltimore, Maryland, USA. Christopher.Bever@va.gov
D015761:4-Aminopyridine / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D017277:Drug Approval / Q000331:legislation & jurisprudence; D006801:Humans; D009103:Multiple Sclerosis / Q000188:drug therapy*; D026902:Potassium Channel Blockers / Q000009:adverse effects / Q000627:therapeutic use*; D014481:United States; D014486:United States Food and Drug Administration
D026902:Potassium Channel Blockers; D015761:4-Aminopyridine